Non-Current Liabilities
Long-Term Debt
Moderna Long-Term Debt remained flat by 0.0% to $590.00M in Q1 2026 compared to the prior quarter.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ4 2024
Last reportedQ1 2026May 1, 2026
How to read this metric
An increase indicates higher leverage and interest expense, while a decrease suggests debt repayment or deleveraging.
Detailed definition
This represents the total value of debt obligations, such as bonds or loans, that are due for repayment beyond the curre...
Peer comparison
Varies significantly by industry; capital-intensive sectors like healthcare often carry higher long-term debt.
Metric ID:
long_term_debtHistorical Data
3 periods
| Q4 '24 | Q4 '25 | Q1 '26 | |
|---|---|---|---|
| Value | $0.00 | $590.00M | $590.00M |
| QoQ Change | — | — | +0.0% |
Range$0.00 – $590.00M
Long-Term Debt at Other Companies
Frequently Asked Questions
- What is Moderna's long-term debt?
- Moderna (MRNA) reported long-term debt of $590.00M in Q1 2026.
- What does long-term debt mean?
- The total amount of debt that is not due for repayment within the next year.